US4670419A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical composition and its rectal use
Assignee: Takeda Pharmaceutical Co Ltd
•
Filing: 1985-07-08
•
Granted: 1987-06-02
•
Expires: 2005-07-08
Abstract
Abstract A pharmaceutical composition containing a hydrophilic drug which is poorly absorbable through the gastrointestinal tract, and cyclodextrin, increases the absorbability of the drug into the mammalian body when administered by a non-oral or non-injection route.
Inventors
- 👤 Yoshiaki Uda
- 👤 Shin-Ichiro Hirai
- 👤 Takatsuka Yashiki
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 23:12
CPC Classifications
A; A61; A61K; A61K47/00; A61K47/50; A61K47/69; A61K47/6949; A61K47/6951; A61K47/30; A61K47/36; A61K47/40; B; B82; B82Y; B82Y5/00; C; C08; C08B; C08B37/00; C08B37/0006; C08B37/0009; C08B37/0012; C08B37/0015; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/13
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
36 words
A method for administering a pharmaceutical composition, which comprises administering a pharmaceutical composition containing a physical mixture of a hydrophilic, physiologically active polypeptide, which is poorly adsorbable through the gastrointestinal tract, and cyclodextrin through the rectum.
Claim 2
Independent Claim
36 words
A method for administering a pharmaceutical composition, which comprises administering a pharmaceutical composition containing a physical mixture of a hydrophilic, physiologically active polypeptide, which is poorly adsorbable through the gastrointestinal tract, and cyclodextrin through the rectum.
Claim 3
Dependent Claim
12 words
A method as claimed in claim 1, wherein the cyclodextrin is α-cyclodextrin.
Claim 4
Dependent Claim
18 words
A method as claimed in claim 1, wherein the pharmaceutical composition is a uniform mixture in dosage form.
Claim 5
Dependent Claim
79 words
A method as claimed in claim 1, wherein the physiologically active polypeptide is selected from the group consisting of L-pyroglutamyl-L-histidyl-L-prolinamide, its salts, a polypeptide represent by the formula: ##STR4## wherein A stands for hydrogen, alkyl, aralkyl, alkoxyalkyl, hydroxyalkyl or alkoxy, R stands for ##STR5## X stands for --CH 2 --, --CH 2 CH 2 -- or --S--, R and each of the other constituent amino acid residues may have an L- or D-configuration or be racemic, and its salts.
Claim 6
Dependent Claim
108 words
A method as claimed in claim 1, wherein the physiologically active polypeptide is selected from the group consisting of luteinizing hormone-releasing hormone (LH-RH) and a peptide which has LH-RH activity and has the formula: (Pyr)Glu-R.sub.1 -Trp-Ser-R.sub.2 -R.sub.3 -R.sub.4 -Arg-Pro-R.sub.5 wherein R 1 stands for His, Tyr, Trp or p-NH 2 -Phe; R 2 stands for Tyr or Phe; R 3 stands for Gly or a D-amino acid residue; R 4 stands for Leu, Ile or Nle; R 5 stands for Gly-NH-R 6 (R 6 stands for H or a lower alkyl group which may optionally have a hydroxyl group) or NH-R 6 (R 6 is as defined above).
Claim 7
Dependent Claim
98 words
A method as claimed in claim 1, wherein the physiologically active polypeptide is selected from the group consisting of insulin, somatostatin, somatostatin derivatives, growth hormone, prolactin, adrenocorticotrophic hormone, melanocyte stimulating hormone, thyrotropin releasing hormone, its salts or its derivatives, thyroid stimulating hormone, luteinizing hormone, follicle stimulating hormone, vasopressin, vasopressin derivatives, oxytocin, carcitonin, parathyroid hormone, glucagon, gastrin, secretin, pancreozymin, cholecystokinin, angiotensin, human placental lactogen, human chorionic gonadotropin, enkephalin, enkephalin derivatives, endorphin, interferon (α, β, γ), urokinase, kallikrein, thymopoietin, thymosin, motilin, dynorphin, bombesin, neutotensin, caerulein, bradykinin, substance P, kyotorophin, nerve growth factor, polymyxin B, colistin, gramicidin, bacitracin, bleomycin and neocarzinostatin.
References Cited (Backward Citations)
GB2090738A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-06-01 | 1990-12-01 | 1991-06-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-06-01 | 1994-12-01 | 1995-06-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-06-01 | 1998-12-01 | 1999-06-02 | $7700.00 | Window Closed / Lapsed |